当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Amal Abd El hafez
Recently, NETosis emerged as a specific type of neutrophil death that is involved in innate immunity, and its products ‘’Neutrophil extracellular traps (NETs)’’ are now implicated as new candidates in a diversity of pathologic states. NET formation in contact to different pathogens or a variety of stimuli, is dependent on nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and involves the generation of reactive oxygen species (ROS). They consist of processed chromatin bound to granular and selected cytoplasmic proteins and act mainly via toll-like receptors (TLRs) signaling pathway. Pathogens trapped in NETs are killed through dual oxidative and non-oxidative mechanisms, even those so large that they cannot be phagocytosed. NETs participate in clot formation in blood vessels and might be cytotoxic to tumor cells. Conversely, different mechanisms were found to mediate the pathogenic role of NETs in different pathological states such as: vascular disorders; severe sepsis; autoimmune diseases; pulmonary disorders; pregnancy related disorders; cancer and otitis media. Thus, molecules that affect the balance of NET induction and destruction or attack the integrity of the NET structure like: NADPH inhibitors; deoxyribonuclease (DNase); blocking antibodies against histones or ROS scavengers can be of therapeutic value.